• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Apixaban
    1 Drug classified under this active ingredient


    All the Active Ingredient Drugs

    Eliquis
    Pfizer
    RX
    partial basket chart
    Eliquis

    Anticoagulant, Direct Factor Xa Inhibitor. Apixaban 2.5 mg, 5 mg.
    F.C. TAB: 60 x 2.5mg, 60 x 5mg
    Preven. of VTE (VTEp): elective hip or
    knee replac. surg.- 2.5 mg ×2/d.
    Init. dose should be taken 12 - 24 hrs.
    after surg.
    In pts. underg. hip replac. surg.- The
    recom. duration of tmt. is 32- 38 d.
    In pts. underg. knee replac. surg.: The
    recom. duration of tmt. is 10- 14 d.
    Preven. of stroke & syst. embol. in pts.
    with non-valvul. atrial fibril. (NVAF):
    5 mg ×2/d.
    Dose reduction: 2.5mg×2/d in pts. with
    NVAF and at least two of the follow.
    characteristics: age ≥ 80 yrs., bdy. wt. ≤
    60 kg, or ser. Cr ≥ 1.5 mg/dL (133
    micromole/L).
    Ther. should be cont. long term.
    Tmt. of DVT, tmt. of PE and preven. of
    recur. DVT &PE (VTEt)
    Tmt. of acute DVT and tmt. of PE is 10
    mg×2/d for the first 7 d. follow. by 5
    mg ×2/d.
    As per avail. med. guidelines, short
    durat. of tmt. (at least 3 mnths.) should
    be based on transient risk factor. (e.g.
    recent surg., trauma, immobilis.).
    Preven. of recur. DVT & PE is 2.5
    mg×2/d. When preven. of recur. DVT &
    PE is indic., the 2.5 mg×2/d should be
    init. follow. complet. of 6 mnths. of tmt.
    5 mg×2/d or with another anticoag.
    See Lit.
    2.5 mg tabs. - Preven. of VTE in adult pts.
    who have undergone elect. hip or knee
    replac. surg.
    Preven. of stroke and syst. embol. in adult
    pts. NVAF, with one/ more risk fact., e.g as
    prior stroke, TIA; age ≥ 75 yrs.; hypertens.;
    diabetes. mell.; symptom. HF (NYHA Class
    ≥ II).
    Tmt. of DVT, PE , and preven. of recur.
    DVT & PE in adult.
    5 mg tabs. - Preven. of stroke, syst. embol.
    in adult pts. NVAF, with one/ more risk
    fact., e.g. prior stroke or TIA; age ≥ 75 yrs.;
    hypertens.; diabetes mell.; symptom. HF
    (NYHA Class ≥ II).
    Tmt. of DVT, PE in adult. 
    C/I: Hypersens.
    Active clinic. signific. bleed.
    Hep. dis. assoc. with coagulopathy
    &clinic. relevant bleed. risk.
    Lesion/ condit. if consid. a signific. risk
    factor for major bleed. This may include
    current or recent GI ulcer., presence of
    malig. neoplasm. at high risk of bleed.,
    recent brain, spinal inj., recent brain,
    spinal or ophthalmic surg., recent
    intracran. haemorrhage, known/
    suspect. esophagi. varices, arterioven.
    malform., vasc. aneurysms or major
    intraspinal or intracerebr. vascular
    abnorm.
    Concom. tmt. with any other anticoag.
    agent e.g. unfraction. heparin (UHF), low
    molec. wt. heparins (enoxaparin,
    dalteparin, etc.), heparin derivat.
    (fondaparinux, etc.), oral anticoag.
    (warfarin, rivaroxaban, dabigatran, etc.)
    except under specific circumstances of
    switching anticoag. ther.or when UHF is
    given at doses necessary to maintain an
    open centr. ven. or arterial catheter.

    CLOSE